| Record Information |
| Version |
3.5 |
| Creation Date |
2005-11-16 08:48:42 -0700 |
| Update Date |
2013-02-08 17:09:14 -0700 |
| HMDB ID |
HMDB00745 |
| Secondary Accession Numbers |
None |
| Metabolite Identification |
| Common Name |
Homocarnosine |
| Description |
Homocarnosine is a normal human metabolite, the brain-specific dipeptide of gamma-aminobutyric acid (GABA) and histidine. (PMID 1266573 ). Increased concentration of CSF homocarnosine has been found in familial spastic paraplegia. (PMID 842287 ). Homocarnosinosis (an inherited disorder, OMIM 236130 ) is characterized by an elevated level of the dipeptide homocarnosine (Hca) in the Cerebrospinal fluid (CSF) and the brain and by carnosinuria and serum carnosinase deficiency, and can co-exist with paraplegia, retinitis pigmentosa, and a progressive mental deficiency. (PMID 3736769 ). In glial tumors of human brain the content of homocarnosine has been found to be lower than in brain tissue (PMID 1032224 ), while an increase in content of homocarnosine was observed in brain tissue of animals under experimental trauma of cranium. (PMID 1025883 ). |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- g-Aminobutyryl-L-histidine
- g-Aminobutyrylhistidine
- gamma-Aminobutyryl-L-histidine
- gamma-Aminobutyrylhistidine
- Homocarnosine
- L-Homocarnosine
- N-(4-Aminobutyryl)-Histidine
- N-(4-Aminobutyryl)-L-Histidine
|
| Chemical Formula |
C10H16N4O3 |
| Average Molecular Weight |
240.259 |
| Monoisotopic Molecular Weight |
240.122240398 |
| IUPAC Name |
(2S)-2-(4-aminobutanamido)-3-(1H-imidazol-4-yl)propanoic acid |
| Traditional IUPAC Name |
(2S)-2-(4-aminobutanamido)-3-(1H-imidazol-4-yl)propanoic acid |
| CAS Registry Number |
3650-73-5 |
| SMILES |
NCCCC(=O)N[C@@H](CC1=CNC=N1)C(O)=O |
| InChI Identifier |
InChI=1S/C10H16N4O3/c11-3-1-2-9(15)14-8(10(16)17)4-7-5-12-6-13-7/h5-6,8H,1-4,11H2,(H,12,13)(H,14,15)(H,16,17)/t8-/m0/s1 |
| InChI Key |
CCLQKVKJOGVQLU-QMMMGPOBSA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Amino Acids, Peptides, and Analogues |
| Class |
Peptidomimetics |
| Sub Class |
Hybrid Peptides |
| Other Descriptors |
- Aromatic Heteromonocyclic Compounds
|
| Substituents |
- Alpha Amino Acid Or Derivative
- Carboxamide Group
- Carboxylic Acid
- Gamma Amino Acid Or Derivative
- Imidazole
- Imidazolyl Carboxylic Acid Derivative
- N Acyl Alpha Amino Acid
- N Substituted Alpha Amino Acid
- Primary Aliphatic Amine (Alkylamine)
- Secondary Carboxylic Acid Amide
|
| Direct Parent |
Hybrid Peptides |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
Not Available |
| Application |
Not Available |
| Cellular locations |
- Cytoplasm (predicted from logP)
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
Not Available |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
Not Available |
Not Available |
| LogP |
Not Available |
Not Available |
|
| Predicted Properties |
|
| Spectra |
|
| 1H NMR Spectrum |
| MS/MS Spectrum Quattro_QQQ 10 |
| MS/MS Spectrum Quattro_QQQ 25 |
| MS/MS Spectrum Quattro_QQQ 40 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 10 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 20 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 30 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 40 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 50 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 10 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 20 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 30 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 40 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 50 |
| MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) |
| MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) |
| [1H,13C] 2D NMR Spectrum |
|
| Biological Properties |
| Cellular Locations |
- Cytoplasm (predicted from logP)
|
| Biofluid Locations |
- Cerebrospinal Fluid (CSF)
- Urine
|
| Tissue Location |
|
| Pathways |
Not Available
|
| Normal Concentrations |
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.70 +/- 2.50 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
0.26 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
|
| Abnormal Concentrations |
|
Not Available |
| Associated Disorders and Diseases |
| Disease References |
None |
| Associated OMIM IDs |
None |
| External Links |
| DrugBank ID |
Not Available |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB022217 |
| KNApSAcK ID |
Not Available |
| Chemspider ID |
8418848  |
| KEGG Compound ID |
C00884  |
| BioCyc ID |
Not Available |
| BiGG ID |
Not Available |
| Wikipedia Link |
Not Available |
| NuGOwiki Link |
HMDB00745  |
| Metagene Link |
HMDB00745  |
| METLIN ID |
270  |
| PubChem Compound |
10243361  |
| PDB ID |
Not Available |
| ChEBI ID |
491179  |
| References |
| Synthesis Reference |
Nagai, Kineshiro; Nagai, Kinuko. Treating inflammatory diseases with homocarnosine. U.S. (1985), 7 pp. |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Petroff OA, Mattson RH, Behar KL, Hyder F, Rothman DL: Vigabatrin increases human brain homocarnosine and improves seizure control. Ann Neurol. 1998 Dec;44(6):948-52.
Pubmed: 9851440
- Petroff OA, Hyder F, Mattson RH, Rothman DL: Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology. 1999 Feb;52(3):473-8.
Pubmed: 10025774
- Lenney JF, Peppers SC, Kucera CM, Sjaastad O: Homocarnosinosis: lack of serum carnosinase is the defect probably responsible for elevated brain and CSF homocarnosine. Clin Chim Acta. 1983 Aug 15;132(2):157-65.
Pubmed: 6616870
- Rothman DL, Behar KL, Prichard JW, Petroff OA: Homocarnosine and the measurement of neuronal pH in patients with epilepsy. Magn Reson Med. 1997 Dec;38(6):924-9.
Pubmed: 9402193
- Pearl PL, Novotny EJ, Acosta MT, Jakobs C, Gibson KM: Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol. 2003;54 Suppl 6:S73-80.
Pubmed: 12891657
- Tell G, Bohlen P, Schechter PJ, Koch-Weser J, Agid Y, Bonnet AM, Coquillat G, Chazot G, Fischer C: Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. Neurology. 1981 Feb;31(2):207-11.
Pubmed: 6258106
- Promyslov MSh, Mirzoian RA: [Homocarnosine metabolism in brain tissue] Vopr Biokhim Mozga. 1976;11:71-7.
Pubmed: 1032224
- Iurovskii SL, Orlov VI, Pogorelova TN, Drukker NA, Madan M: [Homocarnosine of the amniotic fluid as an indicator of fetal cerebral lesions] Akush Ginekol (Mosk). 1989 Sep;(9):45-7.
Pubmed: 2596637
- Menachem EB, Persson LI, Schechter PJ, Haegele KD, Huebert N, Hardenberg J, Dahlgren L, Mumford JP: Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy. Epilepsy Res. 1988 Mar-Apr;2(2):96-101.
Pubmed: 3143561
- Perry TL, Kish SJ, Sjaastad O, Gjessing LR, Nesbakken R, Schrader H, Loken AC: Homocarnosinosis: increased content of homocarnosine and deficiency of homocarnosinase in brain. J Neurochem. 1979 Jun;32(6):1637-40.
Pubmed: 448356
- Promyslov MSh, Mirzoian RA: [Study of homocarnosine metabolism in the brain tissue in diseases of the nervous system] Vopr Med Khim. 1976 Mar-Apr;22(2):209-12.
Pubmed: 1025883
- Manyam BV, Bhatt MH, Moore WD, Devleschoward AB, Anderson DR, Calne DB: Bilateral striopallidodentate calcinosis: cerebrospinal fluid, imaging, and electrophysiological studies. Ann Neurol. 1992 Apr;31(4):379-84.
Pubmed: 1586138
- Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4.
Pubmed: 19212411
|